Santos falls as oil slide weighs on ASX energy stocks

Santos falls as oil slide weighs on ASX energy stocks

June 15, 2026

Sydney, June 16, 2026, 05:05 AEST

  • Santos ended the session at A$7.39, dropping 8.43% as oil-linked names sold off hard on the ASX.
  • Brent crude dropped over 4% as market players unwound the war-linked supply “risk premium.” That’s the price added on fears of possible supply trouble. Reuters
  • Santos has its next big event with the 2026 second-quarter report coming out on July 23, according to the investor calendar.

Santos Limited shares tumbled Monday, sliding with the ASX energy sector while the broader Australian market pushed higher. The stock ended at A$7.39, off 8.43% from its last close at A$8.07. The session saw Santos trade between A$7.35 and A$7.94, according to Investing.com, with a 52-week range of A$5.90 to A$8.24. The drop came as the S&P/ASX 200 touched a two-month high, but energy names fell 5.06% after crude oil retreated.

Santos shares got hit because it’s an oil and gas company, and when crude drops, so do projected sales and cash flow. Brent crude slid $4.11, or 4.71%, to $83.22 a barrel by early Monday afternoon in New York. WTI crude was down 5.11% at $80.54. Reuters reported the drop came after the U.S. and Iran made moves to reopen the Strait of Hormuz. “With a wall of oil supply very possibly on the way, the selloff looks justified,” Dennis Kissler, trading SVP at Bok Financial, said to Reuters. Reuters

Santos shares dropped as traders repriced energy risk, rather than reacting to fresh company trouble. Oil stocks usually rally when geopolitical worries push up expectations for tighter supply and stronger realised prices — what producers actually get after contracts and quality adjustments. But those same stocks can give back gains once disruption fears ease. According to Reuters, Woodside slipped in early ASX trading as oil retreated, and Santos was down 4.3% at that stage. Later market figures showed Santos fell further by the close.

The bull thesis is still on the table. Santos hit first oil at the Pikka Phase 1 project in Alaska in May. Reuters said Pikka should hit a gross production plateau of 80,000 barrels of oil per day in the third quarter of fiscal 2026. First sales revenue is expected two to three months after first oil. Santos operates Pikka with a 51% stake. Repsol holds 49%. The company is guiding for 101 million to 111 million barrels of oil equivalent of production for 2026, up from 87.7 mmboe in 2025, lifted by Barossa LNG and Pikka. LNG stands for liquefied natural gas, gas cooled to liquid for transport by ship.

Monday’s drop showed how much Santos has relied on strong oil prices lately. If the U.S.-Iran deal sticks and crude keeps sliding, Santos risks lower realized prices just as investors want clear signs Pikka and Barossa can cover big project bills with steady cash flow. The next big milestone is the July 23 quarterly report: watch for output, first Pikka sales, Barossa and Darwin LNG, and whether Santos can keep a lid on costs. At A$7.39, the stock is fair-to-risky rather than plainly attractive—cheaper than it was last week, but still tied to oil and execution risk.

Mateusz Brzeziński

Mateusz Brzeziński is a financial and technology journalist at Bez-kabli.pl, covering stocks, artificial intelligence, semiconductors and global market developments. He graduated from the Prague University of Economics and Business in the Czech Republic and previously worked in financial analysis before moving into business journalism. His reporting focuses on the companies, technologies and market trends shaping the global economy.

Stock Market Today

  • CSL (ASX: CSL) Trades Below Peers on Recovery Concerns, Bull Case Still in Play
    August 12, 2026, 7:18 PM EDT. CSL Ltd (ASX: CSL) has bounced from lows around $90, now trading near $138.44, but the stock is still below where it was. Shares sit at a 17 times price-to-earnings (PE) ratio based on forecast earnings for FY26 and FY27, which is lower than the biotech sector median PE of 22.5 and well below Eli Lilly at about 30. The discount reflects issues for CSL-cut guidance for FY26, softer albumin prices in China, more impairments, plus questions around leadership. Still, CSL's base in immunoglobulin, plasma, and vaccines supports its longer-term growth story. The company sees demand running mid-to-high-single digits as unmet medical need remains a driver. The market is pricing in the uncertainty, but some see value in CSL shares with FY26 results coming August 18.